AIM VACCINE News

AIM VACCINE: Terms of Reference of the Remuneration and Appraisal Committee of the Board of Directors

Apr 19 07:12 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER

Apr 18 07:44 ET

AIM VACCINE: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 3 05:02 ET

AIM VACCINE: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Apr 3 04:56 ET

AIM VACCINE: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Apr 3 04:48 ET

AIM VACCINE: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Apr 3 04:38 ET

AIM VACCINE: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023

Apr 3 04:31 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE SUBMIT

Mar 27 20:03 ET

AIM VACCINE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Mar 27 20:02 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED

Mar 27 20:00 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR NOVEL-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE SUBMITTED

Mar 26 09:20 ET

AIM VACCINE: NOTICE OF BOARD MEETING

Mar 15 04:30 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED

Mar 3 19:00 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II CLINICAL TRIAL OF TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE

Mar 3 18:54 ET

AIM VACCINE: PROFIT WARNING

Mar 3 18:50 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE RABIES VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES

Mar 3 18:47 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE PNEUMONIA VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES

Mar 3 18:41 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - EXPECTED COMPLETION OF APPLICATION FOR MARKETING OF 13-VALENT PNEUMONIA CONJUGATE VACCINE, ITERATIVE SERUM-FREE RABIES VACCINE AND 23-VALENT PNEUMONIA POLYSACCHARIDE VACCINE IN 2024

Mar 3 18:30 ET

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR MARKETING REGISTRATION FOR 13-VALENT PNEUMONIA CONJUGATE VACCINE SUBMITTED

Mar 1 05:37 ET

AIM VACCINE: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 1 03:38 ET